Sustained administration of opioid antagonists to rodents results in an enhanced antinociceptive response to agonists. We investigated the changes in spinal m-opioid receptor signalling underlying this phenomenon. Rats received naltrexone (120 mg/h; 7 days) via osmotic minipumps. The antinociceptive response to the m-agonist sufentanil was tested 24 h after naltrexone withdrawal. In spinal cord samples, we determined the interaction of m-receptors with Ga proteins (agonist-stimulated [ ]GTPgS binding, potentiated the inhibitory effect of DAMGO on the AC/cAMP pathway, and increased the inverse agonist effect of naltrexone on cAMP accumulation. In control rats, the inhibitory effect of DAMGO on cAMP production was antagonized by pertussis toxin (PTX) whereas, after chronic naltrexone, the effect became resistant to the toxin, suggesting a coupling of m-receptors to PTX-insensitive Ga z subunits. Immunoprecipitation assays confirmed the transduction switch from Ga i/o to Ga z proteins. The consequence was an enhancement of the antinociceptive response to sufentanil that, in consonance with the neurochemical data, was prevented by Ga z -antisense oligodeoxyribonucleotides but not by PTX. Such changes in opioid receptor signalling can be a double-edged sword. On the one hand, they may have potential applicability to the optimisation of the analgesic effects of opioid drugs for the control of pain. On the other hand, they represent an important homeostatic dysregulation of the endogenous opioid system that might account for undesirable effects in patients chronically treated with opioid antagonists.
Introduction
Opioid drugs produce their pharmacological effects by interacting with specific G-protein-coupled receptors (namely m-, d-and k-opioid receptors) (Snyder and Pasternak, 2003) . The functional interaction of opioid receptors with the pertussis toxin (PTX)e sensitive Ga i1,2,3 and Ga o transducers as well as PTX-resistant Ga z has been clearly demonstrated in heterologous expression systems, neural cell lines and in the CNS ChaleckaFranaszek et al., 2000; Tso and Wong, 2000) . In animal models, evidence that Ga i1,2,3 , Ga o , Ga z and Ga q can contribute to m-opioid signalling and antinociception was provided by studies using PTX, specific antisera or antisense oligodeoxyribonucleotides against specific G-protein subunits and null transgenic mouse strains (Sanchez-Blazquez et al., 1995 Standifer et al., 1996; Garzón et al., 1998; Hendry et al., 2000; Yang et al., 2000; Yoburn et al., 2003; Mostany et al., 2008; Lamberts et al., 2011) . In addition to the specificity of receptoreG-protein coupling, different selective agonists for a specific receptor can induce different modes of ligandereceptor interaction, and the particular activation pattern of G-protein subtypes determines the intrinsic activity of the agonist for the elicited biological response (Garzón et al., 1998; Sanchez-Blazquez et al., 2001; Valdizan et al., 2010) .
One of the best-characterised effector systems linked to the opioid receptor signalling cascade is the adenyl cyclase (AC)/cAMP pathway (Law et al., 2000) . Following receptor activation, opioid drugs exert an inhibitory effect on AC activity through Ga i subunits, resulting in reduced cAMP production (George et al., 2000; Laugwitz et al., 1993; Mostany et al., 2008) . The AC/cAMP pathway has long been known to play a crucial role in the processing of painful stimuli, and studies have demonstrated an important role of several AC isoforms in inflammatory and neuropathic pain models, as well as in opioid-induced analgesia (see Pierre et al., 2009) .
Chronic treatment with opioid ligands (agonists and antagonists) as well as other non-opioid drugs (for example, calcium channel blockers) critically modifies, quantitatively and qualitatively, opioid receptor signalling. This modification results in important changes in the pharmacological potency, efficacy and intrinsic activity of opioid drugs as well as in the quality of the elicited response (Bannister and Dickenson, 2010; Chang et al., 2007; Diaz et al., 2000; Dierssen et al., 1990; Gullapalli and Ramarao, 2002; Hurlé et al., 2000; Mostany et al., 2008; Santillán et al., 1998; Vanderah et al., 2001) . In this context, the development of functional super-sensitivity to opioid agonists after long-term exposure to opioid receptor antagonists, such as naloxone, naltrexone and 6b-naltrexol, is a well-known phenomenon in rodents (Sirohi et al., 2007) . For example, we previously reported that the antinociceptive and respiratory depressant potencies of m-agonists are enhanced following interruption of long-term treatment with naltrexone in rats (Diaz et al., 2002) . In most of the studies in the literature, this increased responsiveness to agonists has been correlated with opioid receptor up-regulation (Diaz et al., 2002; Lesscher et al., 2003; Patel et al., 2003; Sirohi et al., 2007; Unterwald et al., 1995; Yoburn et al., 1986) .
Sustained opioid receptor blockade by naltrexone is among the currently available treatments for substance abuse and dependence disorders, and the recently introduced long-acting, sustained-release formulations of naltrexone are considered to be promising strategies for the treatment of heroin (Krupitsky and Blokhina, 2010) , alcohol (Anton, 2008; Ray et al., 2010) and nicotine (David et al., 2006) dependence. However, the advantages and disadvantages of these new therapies have not been systematically analysed.
The neurochemical adaptations produced by continued opioid antagonist treatment have scarcely been studied. Here, we further analyse the molecular mechanisms underlying the increased functional responsiveness to opioid agonists produced by sustained administration of antagonists in rats. We demonstrate that following long-term treatment with naltrexone, spinal m-opioid receptors undergo a transductional shift from PTX-sensitive Ga i/o to PTX-resistant Ga z transducer proteins. Consequently, the inhibitory effect of agonists on the AC/cAMP effector pathway is enhanced.
In addition, the population of constitutively active m-receptors in the spinal cord appears to be increased. These neurochemical changes correlate with the pharmacological super-sensitivity to the antinociceptive effect of the m-opioid agonist sufentanil.
Materials and methods

Subjects
The experiments were carried out using male SpragueeDawley rats weighing 250e300 g (Charles River, Harlan, Barcelona, Spain). The animals were housed in sawdust-lined cages in an environmentally controlled animal facility at 22 C with a 12:12 h lightedark cycle and food/water provided ad libitum. This study was approved by the Cantabria University Institutional Laboratory Animal Care and Use Committee and performed in strict accordance with the "European Directive for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes" (European Union Directive #86/606/EEC).
Pharmacological treatments
Diagrams showing the pharmacological treatment schedules are depicted in Supplementary figure S1. Chronic saline (1 ml/h) or naltrexone (120 mg/h) infusion was administered using Alzet 2001 osmotic minipumps (Alza Corporation, Palo Alto, CA, USA) that were implanted subcutaneously under light ether-induced anaesthesia ( Figure S1A ). These pumps delivered the solutions at a constant rate of 1 ml/h for 7 days. On day 7, the minipumps were removed, and the in vivo (antinociceptive response to the m-opioid receptor agonist sufentanil) or in vitro assays (autoradiographic, [ 35 S]GTPgS binding and adenylyl cyclase studies) were carried out 24 h after withdrawal from a chronic saline or naltrexone treatment.
To interfere with the expression of Ga z proteins, we used a synthetic antisense oligodeoxynucleotide (ODN) that has previously been characterised (SanchezBlazquez et al., 1995; Serres et al., 2000) . The sequence was 5 0 -CGTGATCT-CACCCTTGCTCTCTGCCGGGCCAGT-3 0 . The ODN was phosphorothioate-modified at the two bases on each end. The sequence of the missense oligodeoxynucleotide was 5 0 -CCCTTATTTACTTTCGCC-3 0 , and it was phosphorothioate-modified at positions 5 0 -CC and GC-3 0 (Sanchez-Blazquez et al., 1995; Serres et al., 2000) . ODNs (5 mg/10 ml) were administered twice intracerebroventricularly (i.c.v) under light isofluoraneinduced anaesthesia with a 24-h interval between administrations ( Figure S1B ). The Ga z -antisense ODN injection was performed on days 5 and 7 for the rats receiving chronic naltrexone treatment ( Figure S1C ). The rats were challenged with sufentanil 24 h later to test whether the antinociceptive response elicited by activation of m-opioid receptors was mediated by Ga z .
To prevent the activation of Ga i1,2,3 /Ga o proteins, PTX was administered (1 mg/10 ml, i.c.v.), and the antinociceptive response of sufentanil was tested 48 h later ( Figure S1D ). PTX was injected on day 6 to the rats receiving chronic naltrexone treatment ( Figure S1E ).
Evaluation of nociception
The tail-flick test was used to assess the nociceptive threshold. A tail-flick response was elicited by applying radiant heat to the surface of the tail. The intensity of the stimulus was adjusted so that control latency was within 3e5 s. A cut-off time of 10 s was established to avoid permanent injury. Tail-flick latencies were measured before the drug injection and 30 min after subcutaneous administration of sufentanil (0.1 or 1 mg/kg; Figure S1 ). This drug administration schedule was based on dose-response curves obtained in previous studies (Diaz et al., 2002) . ]GTPgS binding using tissue sections was performed as described previously (Sim et al., 1996; Mostany et al., 2008) . Sections were first preincubated in assay buffer (50 mM TriseHCl, 3 mM MgCl 2 , 0.2 mM EGTA and 100 mM NaCl; pH 7.4) for 15 min at 25 C, followed by a second 15-min preincubation in the same assay buffer containing 2 mM GDP and 10 mU/ml adenosine deaminase. Sections were then incubated for 2 h at 25 C in assay buffer containing 1 mM DTT and 0.04 nM [ 35 S]GTPgS. Consecutive sections were used to define basal binding (in the absence of the opioid agonist), stimulated binding (in the presence of agonist) and non-specific binding (without agonist and in the presence of 10 mM GTPgS) (Diaz et al., 2002 Spinal cord samples were homogenised [1:30 (w/v)] in ice-cold buffer (50 mM TriseHCl, 250 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, and 1 mM DTT; pH 7.4) using a motor-driven glass Teflon tissue potter (10 strokes, 1500 rpm). The homogenates were then centrifuged (1500 x g, 5 min, 4 C), and the resulting supernatants were centrifuged again (14,000 rpm, 15 min, 4 C). Resuspended pellets (500 mg protein/ ml/assay) were incubated with 20 nM [ 35 S]GTPgS and 10 mM DAMGO in a final volume of 100 ml for 30 min at 30 C. Non-specific binding was determined in the presence of 10 mM of GTPgS. Membrane suspensions were then solubilised on ice with in a solution containing 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 2.5 mM CHAPS, 0.1 mM phenylmethylsulfonylfluoride, 0.01 M aprotinin, 1 mg/ml leupeptin, 1 mg/ml pestatin, 1 ml/ml antipain, and 10 mg/ml chymostatin for 30 min. Solubilised membranes were incubated for 3 h at room temperature with 15 ml of specific rabbit anti-Ga o , anti-Ga i1,2,3 and anti-Ga z antibodies immobilised to superparamagnetic Dynabeads Ò Protein A (overnight, 4 C). After three washes with 1 ml of PBS, the beads were pelleted, and the bound radioactivity was counted in 4 ml of Ecolite scintillation cocktail. Antibody specificity was confirmed in our experimental conditions by western blot analysis, as previously described (Mato et al., 2010) .
The amount of coupling of m-opioid receptors to the diverse G-protein subunits induced by DAMGO (10 À4 M) was expressed as percentage over the basal values in the absence of the agonist (100%).
Cyclic AMP assays
AC assays were performed using spinal cord samples as described previously (Mostany et al., 2008) . Samples were homogenised (1:60 weight/volume dilution) with a Teflon/glass grinder (10 strokes, 800 r.p.m.) in an ice-cold homogenisation buffer (20 mM TriseHCl, 1 mM EGTA, 5 mM EDTA, 5 mM DTT, 25 mM leupeptin and 300 mM sucrose; pH 7.4). The homogenates were centrifuged at 1500 x g (5 min at 4 C), and the resulting supernatants were centrifuged at 13,000 x g (15 min at 4 C).
The pellets were resuspended (120 mg protein/ml) in assay buffer (80 mM TriseHCl, 0.2 mM EGTA, 1 mM EDTA, 2 mM MgCl 2 , 100 mM NaCl, 60 mM sucrose, 1 mM DTT, 10 mM GTP, 0.5 mM IBMX, 5 mM phosphocreatine, 50 U/ml creatine phosphokinase, and 5 U/ml myokinase; pH 7.4) without (basal AC activity) or with 10 mM forskolin (FK) (FK-stimulated cAMP accumulation). Opioid receptor-mediated inhibition of FK-stimulated cAMP accumulation was determined using different concentrations of the agonist DAMGO (10 Membranes under the different experimental protocols were preincubated for 5 min at 37 C, then ATP was added to a final concentration of 200 mM and the mixture was incubated for 10 min at 37 C. The reaction was stopped by boiling for 5 min, and the cAMP concentration was determined in a 50 ml sample of the supernatant using a commercial kit (Cyclic AMP [ 3 H] assay system, Amersham Biosciences, Barcelona, Spain). Each cAMP assay was performed in triplicate, and the results are expressed as pmol cAMP/min/mg protein. 
Drugs and chemicals
Data analysis
Data analysis was performed using the GraphPad Prism statistical software package (GraphPad Software, Inc., San Diego, CA, USA). Data from the [ 35 S]GTPgS binding and AC assays were fitted to sigmoidal concentration-response curves to determine potency (EC 50 and IC 50 , respectively) and theoretical maximal effect (E max and I max , respectively). The EC 50 and IC 50 values were normalised as Àlog EC 50 (pEC 50 ) and Àlog IC 50 (pIC 50 ) for statistical comparison. Data represent the mean AE standard error of the mean (S.E.M.). Statistical analysis was performed using Student's t-tests and one-way ANOVA followed by the NewmaneKeuls post-hoc test when appropriate. A p < 0.05 was considered to be statistically significant. (Table 1 ; Fig. 1 ). These data suggest that the m-opioid receptor coupling to G-proteins was increased following chronic naltrexone treatment.
Results
Chronic naltrexone treatment increases DAMGO-induced [
We also confirmed that chronic naltrexone treatment increased the specific binding of 3 H-DAMGO to m-opioid receptors (Diaz et al., 2002; ) , consistent with the reported up-regulation of m-opioid receptors induced by chronic naltrexone treatment (Yoburn et al., 1986 (Yoburn et al., , 1995 Unterwald et al., 1995; Lesscher et al., 2003; Patel et al., 2003; Sirohi et al., 2007) .
Chronic naltrexone treatment causes potentiation of m-opioid
agonist-induced inhibition of cAMP accumulation through a mechanism involving PTX-resistant G-proteins Basal AC activity and the ability of the AC activator FK (10 mM) to increase cAMP levels were not altered following long-term administration of naltrexone in comparison with saline-treated animals ( Table 1) . In control rats, incubation of the spinal cord membranes with increasing concentrations (10 À9 e10 À4 M) of the selective m-opioid agonist DAMGO produced a concentration-dependent inhibition of FK-stimulated cAMP accumulation. Following long-term treatment with naltrexone, the maximal ability of DAMGO to inhibit FK-induced cAMP accumulation was significantly enhanced with no change in potency (Table 1) . PTX causes the ADP-ribosylation and inactivation of Ga i/o proteins, with the exception of Ga z (Casey et al., 1990) . The presence of PTX in the medium did not modify either basal or FK-stimulated cAMP accumulation (Table 1, Fig. 2 ). However, in saline-treated animals, the maximal inhibitory effect of DAMGO was almost completely prevented by PTX pretreatment, suggesting the involvement of Ga i/o proteins. On the contrary, in the group of animals chronically treated with naltrexone, PTX did not antagonise the maximal inhibitory effect of DAMGO on FK-induced cAMP accumulation, suggesting the involvement of Ga z proteins (Fig. 2) . In spinal cord homogenates from animals treated with chronic naltrexone, the coupling of m-opioid receptors to Ga proteins was significantly increased in comparison with saline-treated animals (183.0 AE 13.3% vs. 140.1 AE 9.0% of basal binding; p < 0.05). Western blot analysis of spinal cord samples revealed no change in the expression of any Ga subunit after chronic naltrexone treatment (see methods and Figure S3 in the supplementary information). However, as shown in Fig. 3 , the DAMGO-induced activation of Ga z subunits was significantly increased in chronic naltrexone-treated animals in comparison with the saline group (301.6 AE 39.9% vs. 170.7 AE 10.2% of basal binding; p < 0.05). Significant differences in the coupling with Ga o (194.4 AE 7.7% vs. 172.6 AE 5.8%) and Ga i1,2,3 (178.9 AE 7.3% vs. 160.6 AE 9.6%) were not observed between naltrexone-and saline-treated animals.
Potentiation of m-opioid antinociception following withdrawal from chronic naltrexone involves Ga z proteins
The functional relevance of the transduction switch from Ga i/o to Ga z proteins was assessed by analysing the consequences of PTX or Ga z -antisense ODN pretreatment on the antinociceptive response to sufentanil. Under baseline conditions (Fig. 4A) , sufentanil, acutely administered at the dose of 1 mg/kg (n ¼ 10), produced an antinociceptive response that almost reached the MPE; this effect was prevented by PTX (1 mg/10 ml, i.c.v.) administered 48 h beforehand (n ¼ 5). In contrast, pretreatment with Ga z -antisense ODN (5 mg/10 ml, two i.c.v. injections on alternate days; n ¼ 5) did not significantly modify the effect of sufentanil. Neither saline nor missense ODN administered i.c.v. modified the tail-flick basal response or sufentanil-induced antinociception. These results indicate that sufentanil-induced antinociception in naïve animals is dependent on the interaction of m-opioid receptors with PTX-sensitive Ga i/o transducer proteins rather than PTX-insensitive Ga z subunits.
In the rats that received the chronic naltrexone treatment (Fig. 4B) , the antinociceptive response of sufentanil (0.1 mg/kg; n ¼ 5) was significantly potentiated, confirming "in vivo" the development of functional super-sensitivity to the antinociceptive effect of sufentanil. PTX injected on the 6th day of chronic naltrexone infusion did not prevent the development of opioid supersensitivity. On the other hand, Ga z -antisense ODN injected i.c.v. on days 5 and 7 of the chronic naltrexone infusion completely prevented the development of super-sensitivity to the antinociceptive response elicited by sufentanil. The reduction in the expression levels of Ga z proteins in the dorsal horn of the spinal cord induced by Ga z -antisense ODN treatment was confirmed by western blotting experiments (Fig. 5) . Overall, these results indicate that following withdrawal from chronic naltrexone, the antinociceptive response mediated by m-opioid receptor activation involved Ga ztransducer proteins.
Chronic naltrexone treatment increases the constitutive activity of m-opioid receptors
Incubation of spinal cord membranes from saline-treated rats with increasing concentrations of naltrexone induced a concentration-dependent increase in the levels of cAMP (E max ¼ 29.1 AE 0.7 pmol/min/mg; pEC 50 ¼ 4.2 AE 0.3). This inverse agonist action of naltrexone was potentiated after chronic administration of naltrexone because the maximal cAMP production appeared significantly enhanced (E max ¼ 35.3 AE 0.8, p < 0.01 vs. saline-treated group; pEC 50 ¼ 4.1 AE 0.2; p ¼ NS), indicating the existence of constitutively active opioid receptors that uncovered the inverse agonist effect of naltrexone (Fig. 6A) .
To determine the subtype of opioid receptor that exhibited constitutive activity, the effect of naltrexone on cAMP levels was evaluated in the presence of selective antagonists to m-(b-funaltrexamine), d-(naltrindole) and k-(nor-binaltorphimine) receptors at a concentration of 10 À4 M. The effect of each antagonist alone was examined in parallel, and only nor-binaltrophimine increased cAMP levels (data not shown), confirming its reported inverse agonism (Wang et al., 2007) . As shown in Figure S4 ).
Nor-binaltrophimine not only was unable to antagonise but also increased naltrexone-induced cAMP accumulation in both the saline group (142.2 AE 2.1%; p < 0.01 vs. the effect of naltrexone alone) and the chronic naltrexone group (165.3 AE 10.1%; p < 0.05 vs. the effect of naltrexone alone). Furthermore, immunoprecipitation assays that were carried out using spinal cord samples from saline and chronic naltrexone-treated animals demonstrated the absence of naltrexone-induced coupling with Ga s (104 AE 8.1%). Overall, our data support the interaction of naltrexone with constitutively active m-opioid receptors. 
Discussion
Functional super-sensitivity to opioid agonists induced by sustained exposure to antagonists is a well-known phenomenon in rodents. Most studies addressing the underlying mechanisms have focused on the up-regulation of opioid receptors in the CNS subsequent to blockade (Diaz et al., 2002; Lesscher et al., 2003; Patel et al., 2003; Sirohi et al., 2007; Unterwald et al., 1995; Yoburn et al., 1986 Yoburn et al., , 1995 . Treatment with naltrexone clearly induces the up-regulation of m-and, to a lesser extent, d-and k-opioid receptors throughout the brain, with differences in the percent change across various brain regions (Lesscher et al., 2003; Yoburn et al., 1995) . Furthermore, the increase in the maximal stimulatory effect of DAMGO on the spinal cord binding of [ Regarding intracellular effectors, one of the best-characterised signalling cascades linked to opioid receptor activation is the AC/cAMP pathway (Law et al., 2000) . This pathway has long been known to play a crucial role in processing nociception. In addition to opioids, other pharmacological agents with analgesic properties exert an inhibitory influence on this pathway (Pierre et al., 2009 ). In agreement with previous reports (George et al., 2000; Laugwitz et al., 1993; Mostany et al., 2008) , we observed that PTX-sensitive Ga i subunits were the preferential transducers linking m-opioid receptor activation to the AC/cAMP pathway in naive animals. Following chronic naltrexone treatment, the inhibitory effect of DAMGO on the AC/cAMP pathway was significantly potentiated. However, under these experimental conditions, the effect was not prevented by PTX, in contrast to the saline-treated group. Thus, our data indicate that following chronic treatment with antagonists, m-opioid receptors underwent a shift in the transduction of their signal, showing a higher efficiency of interaction with PTX-resistant over PTX-sensitive Ga proteins. A likely transducer candidate is Ga z , which is the only Ga subunit resistant to PTX (Casey et al., 1990) that inhibits AC (Kozasa and Gilman, 1995; Mostany et al., 2008) . Consistent with this assumption, the immunoprecipitation data indicated that the coupling of m-opioid receptors to Ga z subunits was augmented following withdrawal from chronic naltrexone, whereas the coupling to Ga o and Ga i1,2,3 subunits remained similar to that observed in saline-treated rats.
Although the present study provides no information about the mechanisms that could explain why the switch from Ga i to Ga z transducer proteins resulted in an enhancement of the opioid inhibitory effect on the AC/cAMP effector pathway, several observations led us to propose some putative mechanisms for such a phenomenon. First, the rate of Ga z GTP hydrolysis is as much as 200-fold slower than that determined for other G-protein a subunits.
This extremely slow rate of GTP hydrolysis would then result in a long-lasting signal (Casey et al., 1990; Jeong and Ikeda, 1998) . Second, the inhibitory Ga subunits differ in their specificity for individual AC isoforms. For example, it has been suggested that the relatively high affinity of Ga z for AC type V, together with its slow GTPase activity, might account for its capacity to induce strong AC inhibition in cultured cells (Ammer and Christ, 2002) . Finally, Ga z may be difficult to switch off after receptor activation unless external factors, such as RGS-Rz proteins, accelerate the rate of Ga z GTP hydrolysis. In particular, RGSZ2 plays an important role in controlling m-opioid signalling induced by Ga z transducer proteins (Garzón et al., 2005) . Thus, it may be feasible that, following chronic naltrexone treatment, an inadequate control of Ga z activity may lead to strong inhibition of the AC/cAMP pathway.
The functional relevance of the particular transducer protein linking m-opioid receptor activation to the AC/cAMP signalling pathway is strengthened by our data that demonstrate the close relationship between agonist-activated signalling "in vitro" and agonist-induced pharmacological effects "in vivo". Thus, as observed in the AC assay, sufentanil-induced antinociception in naive rats was prevented by PTX but not by Ga z -antisense ODN, indicating the involvement of Ga i/o transducer proteins. In contrast, following withdrawal from chronic naltrexone treatment, the switch from Ga i/o to Ga z proteins appeared to be responsible for the enhanced antinociceptive response to m-opioid agonists because sufentanil- ( Law et al., 2000; Heinke et al., 2011) , whose modulation by Ga z has been described in several reports (see Ho and Wong, 2001) . Moreover, G bg -subunits broadly regulate Kir3 channels, voltagegated Ca 2þ channels, phospholipase Cb, and several isoforms of AC, among other effectors (Dupré et al., 2009 ). In addition to chronic naltrexone treatment, a number of pharmacological interventions induce analogous signalling plasticity on m-opioid receptors with similar functional consequences. In this regard, we previously reported that 7 days of combined treatment with nimodipine (L-type calcium channel blocker) and sufentanil prevents the development of tolerance and strongly enhances the antinociception in rats (Diaz et al., 2000; Dierssen et al., 1990; Hurlé et al., 2000; Mostany et al., 2008) . The underlying mechanism involved efficient inhibition of cAMP production associated with a change in m-opioid receptor-preferred G-protein coupling from PTX-sensitive Ga i to PTX-resistant Ga z subunits (Mostany et al., 2008) . Changes in sensitivity to agonists have also been reported to occur upon heterodimerisation of opioid receptors. Studies using cultured cells provide evidence that d-selective antagonists enhance m-opioid receptor signalling through a mechanism involving the formation of med hetero-oligomeric signalling units and a subsequent switch in opioid receptor preference for Ga z over Ga i subunits, which are preferentially activated by individually expressed m-and d-receptors (Fan et al., 2005; George et al., 2000; Hasbi et al., 2007) .
Experiments in vivo demonstrate that this change in opioid receptor transduction leads to increased m-receptor binding and signalling activity and to an enhancement of morphine antinociceptive potency in mice (Abul-Husn et al., 2007; Gomes et al., 2004) . Taken together, these findings suggest that conditions favouring the coupling of m-opioid receptors to Ga z -protein subunits would increase agonist-induced AC/cAMP signalling pathways, leading to an enhancement of the pharmacological responses.
Another relevant adaptive response prompted by sustained opioid receptor blockade arises from the observation that the inverse agonist effect of naltrexone on the AC activity was significantly potentiated. Opioid receptors, similar to other G-proteincoupled receptors, may exhibit spontaneous constitutive activity even in the absence of agonists (Sadee et al., 2005) . It has also been reported that antagonists, such as naloxone and naltrexone, display inverse agonist activity when the population of constitutively active opioid receptors increases, which is typically more prominent following chronic treatment with opioid agonists (Liu and Prather, 2001; Wang et al., 2001 Wang et al., , 2007 . On the other hand, the in vitro inverse agonist activity of naltrexone and other putative m-inverse agonists has been questioned by Divin et al., 2009 . These authors observed that, under chronic treatment and the subsequent rapid removal of opioid agonist, cells expressing m-opioid receptors exhibit an enhanced cAMP accumulation not linked to the formation of constitutively active m-opioid receptors.
Our present results demonstrate for the first time in native tissue that the inverse agonism of naltrexone, reflected by cAMP accumulation, occurs after sustained treatment with opioid antagonists. Furthermore, our findings support the fact that the stimulatory effect of naltrexone on cAMP accumulation was mediated by m-opioid receptors. In addition, immunoprecipitation assays indicated the lack of involvement of Ga s subunits in this effect, demonstrating that naltrexone could not induce the coupling of m-opioid receptors to these stimulatory subunits. Considering that receptor over-expression leads to a proportional increase in the number of spontaneously active receptors (see Leurs et al., 1998) , constitutive signalling may be enhanced after withdrawal from chronic naltrexone treatment as a consequence of m-opioid receptor up-regulation. However, sensitisation of the receptor to the effects of inverse agonists cannot be ruled out (Divin et al., 2008; Liu and Prather, 2001; Wang et al., 2007) .
Interestingly, we observed a potentiation of naltrexone inverse agonism by the k-opioid antagonist nor-binaltorphimine. In this regard, Wang et al. (2007) demonstrated that naltrexone has inverse agonist properties at m-but not at d-and k-opioid receptors in cultured cells over-expressing opioid receptors. In this study and in our study (data not shown), nor-binaltorphimine exhibited inverse agonist activity at k-receptors. Thus, such an increase in cAMP accumulation induced by naltrexone in the presence of nor-binaltorphimine may be explained by the sum of their respective inverse agonist effects on m-and k-receptors.
Conclusions
Following long-term treatment with naltrexone, m-receptors in the spinal cord experienced a transduction shift from PTX-sensitive Ga o and Ga i1,2,3 proteins to PTX-resistant Ga z proteins. As a result, the inhibitory effect of the m-agonist DAMGO on the AC/cAMP effector pathway was enhanced. In addition, constitutively active m-opioid receptor expression, and possibly k-opioid receptor expression, in the spinal cord appeared to be increased. The functional consequence of these neurochemical changes is the development of pharmacological super-sensitivity to the antinociceptive effect of m-receptor agonists, such as sufentanil. Such changes in opioid receptor signalling activity can be a double-edged sword. On the one hand, they may have potential applicability to the optimisation of the analgesic effects of opioid drugs for the control of pain. On the other hand, they represent an important homeostatic dysregulation of the endogenous opioid system that might account for undesirable paradoxical pharmacological effects in patients chronically treated with certain opioid antagonists.
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